European Annals of Allergy and Clinical Immunology THE OFFICIAL JOURNAL OF AAITO THE OFFICIAL JOURNAL OF SPAIC HOME PAGE
EDITORS IN CHIEF
L. Cecchi (Italy)
P. Carreiro-Martins (Portugal)

DEPUTY EDITORS
R. Rodrigues Alves (Portugal)
M.B. Bilò (Italy)
 
ASSOCIATE EDITORS
R. Asero (Italy)
M. Branco Ferreira (Portugal)
E. Scala (Italy)
D. Solé (Brasil)
G. Sturm (Austria)

EDITORIAL BOARD
I. Agache (Romania)
I. Annesi Maesano (France)
L. Antonicelli (Italy)
G. Azizi (Iran)
L.M. Borrego (Portugal)
K. Brockow (Germany)
S. Bavbek (Turkey)
E. Cichocka-Jarosz (Poland)
M. Cugno (Italy)
L. Delgado (Portugal)
P. Demoly (France)
G. D'Amato (Italy)
S. Durham (UK)
M. Faber (Belgium)
M. Fernandez-Rivas (Spain)
J. Fonseca (Portugal)
ZS. Gao (China)
G.P. Girolomoni (Italy)
E. Goudouris (Brasil)
A. Grumach (Brasil)
G. Kostantinou (Greece)
F. Levi-Shaffer (Israel)
M. Maurer (Germany)
L. Mayorga (Spain)
C. Micheletto (Italy)
M. Morais de Almeida (Portugal)
G. Moscato (Italy)
A. Musarra (Italy)
C. Nunes (Portugal)
M. Ollert (Lussemburgo)
P. Parronchi (Italy)
G. Passalacqua (Italy)
E. Pedro (Portugal)
A. Perino (Italy)
O. Quercia (Italy)
A. Romano (Italy)
G. Scadding (UK)
A. Todo Bom (Portugal)
A. Tedeschi (Italy)
R. van Ree (Netherland)
D. Villalta (Italy)
S. Voltolini (Italy)

FOUNDERS
F. Bonifazi (Italy)
A. Sabbah (France)
************************* 

Chief Business & Content Officer
Ludovico Baldessin

Editorial Coordinator
Barbara Moret

Publishing Editor
Greta Schincaglia
g.schincaglia@lswr.it
Ph. 0039 (0)2-88184.512

Production Manager
Paolo Ficicchia
p.ficicchia@lswr.it
Ph. 0039 (0)2-88184.222

Sales
Stefano Busconi
dircom@lswr.it
Ph. 0039 (0)2-88184.404

Printing
Mccgraphics Pol. Ind. 
Txirrita Maleo Pab 11 20100 
Errenteria (Gipuzkoa), Spain

EDRA SpA 
Via G. Spadolini, 7
20141 Milano - Italy
Ph. 0039 (0)2-88184.1
Fax 0039 (0)2-88184.301
www.edizioniedra.it
Contents »

Are currently available biomarkers useful to discriminate CSU patients not controlled by low dose omalizumab maintenance therapy?


R. Asero r.asero@libero.it

Show more: Authors information and Publication history

Doi
http://doi.org/10.23822/EurAnnACI.1764-1489.139

Summary

In patients with chronic spontaneous urticaria (CSU), low dose omalizumab maintenance therapy is effective in about one half of complete, fast responders to the drug. Omalizumab 150 mg/month was given as maintenance therapy to 21 patients with a history of severe CSU showing a complete (UAS7= 0) response to the dose of 300 mg/month. After 2 months of such regimen, patients were divided into controlled (n= 14; UAS7= 0) and not controlled (n= 7; UAS7 > 10) and ESR, CRP, total IgE, and D-dimer were measured. The two groups did not differ in any of the biomarkers considered, nor in disease duration or in pre-treatment UAS7 score. The study confirms that it is possible to halve the dose of Omalizumab without any loss of efficacy in a subgroup of patients with CSU but that none of the currently available biomarkers is able to predict which patients will lose disease control following omalizumab dose reduction.

Key words

Chronic Urticaria; Omalizumab; Biomarkers; IgE; D-dimer

FULL TEXT